期刊
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
卷 11, 期 4, 页码 563-576出版社
OXFORD UNIV PRESS
DOI: 10.1017/S1461145707008309
关键词
Electrophysiology; review; schizophrenia; transcranial magnetic stimulation; treatment
资金
- NARSAD Brian Bass Young Investigator Award
- Janssen Translational Neuroscience Fellowship
- NIH [MH60884, MH069895]
- Stanley Foundation
- American Foundation for Aging Research
- Dana Foundation
- NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060884, K23MH076976, R01MH069895] Funding Source: NIH RePORTER
Transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS) have been used increasingly over the past few years to study both the pathophysiology of schizophrenia as well as the utility of focal neuromodulation as a novel treatment for schizophrenia. rTMS treatment studies to date have explored its effect on both positive and negative symptoms by targeting cortical regions thought to underlie these symptom clusters. Studies on auditory hallucinations have been largely positive, while efficacy for negative symptoms is equivocal. A better understanding of the functional abnormalities that accompany symptoms may facilitate the development of rTMS as a treatment modality. Furthermore, schizophrenia patients appear to have abnormal cortical inhibition, consistent with GABA and dopamine abnormalities in schizophrenia. The effect of TMS on GABA and dopamine neurotransmission has not been clearly delineated. Given the variability in cortical response to rTMS in schizophrenia, methods to optimize dosage are essential. Consideration of these factors among others may broaden the scope of utility of TMS for schizophrenia as well as enhance its efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据